YTHDF2 Is a Therapeutic Target for HCC by Suppressing Immune Evasion and Angiogenesis Through ETV5/PD-L1/VEGFA Axis.
Wen J, Xue L, Wei Y, Liang J, Jia W, Yong T, Chu L, Li H, Han S, Liao J, Chen Z, Liu Y, Liu Q, Ding Z, Liang H, Gan L, Chen X, Huang Z, Zhang B.
Wen J, et al. Among authors: jia w.
Adv Sci (Weinh). 2024 Apr;11(13):e2307242. doi: 10.1002/advs.202307242. Epub 2024 Jan 21.
Adv Sci (Weinh). 2024.
PMID: 38247171
Free PMC article.